Stock Information

• Ocugen shares are trading lower after the company announced topline 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy secondary to dry age-related macular degeneration. Key findings include a 31% reduction in lesion growth in the optimal dose group compared to control.
  Tue, Mar 24, 2026 8:17 AM
• Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration Demonstrates Statistically Significant Reduction In Lesion Growth
  Tue, Mar 24, 2026 7:48 AM
• Ocugen shares are trading higher after the company announced that it will host a conference call and webcast to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy, late-stage dry age-related macular degeneration.
  Mon, Mar 23, 2026 9:13 AM
• Ocugen To Present Full Phase 2 ArMaDa Data For OCU410 Gene-Agnostic Modifier Gene Therapy For Geographic Atrophy In March 24 Webcast
  Mon, Mar 23, 2026 7:16 AM
• Ocugen shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $12 price target.
  Tue, Mar 17, 2026 11:07 AM
• Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12
  Tue, Mar 17, 2026 9:44 AM

Financial data not available